VL advised Biotech company Mirxes as Singapore counsel on its IPO and HKEX listing

We are proud to have supported Biotech company Mirxes as Singapore counsel in its initial public offering and listing on the Hong Kong Stock Exchange. The gross proceeds from the offering amounted to approximately HK$1.09 billion. Mirxes is a micro ribonucleic acid (miRNA) technology company headquartered in Singapore, making diagnostic solutions for the screening of diseases available across Singapore and China in addition to other Asian markets. GASTROClear, its key product is the first and only approved molecular IVD product for gastric cancer screening globally.